admin@ataxiatelangiectasia.es
Início
O que é A-T?
Notícias
Pesquisar
News
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
Acessos: 215
EryDex
Quince Therapeutics
ChromaDex wins orphan designation for rare ataxia drug
Acessos: 333
EryDex
Nicotinamide Riboside
ChromaDex
FDA
Nanopore Long-Read Sequencing Facilitates Diagnosis of Atypical Ataxia-Telangiectasia
Acessos: 201
Korea
late onset variant
Nanopore
Neurology Genetics
IBEC and AEFAT join forces against ataxia telangiectasia
Acessos: 120
Spain
AEFAT
IBEC
Organoids to study ataxia telangiectasia
Acessos: 145
Spain
IBEC
organoids
Boston Children's Hospital lab trying to develop drug to treat boy's deadly rare disease
Acessos: 173
ASO
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Acessos: 83
EryDex
FDA
Quince Therapeutics
Governor of Queensland Celebrates Ataxia Telangiectasia Clinical Trial
Acessos: 119
Australia
Triheptanoin
Acasti reports results from ataxia telangiectasia therapy trial
Acessos: 227
GTX-102
Acasti Pharma
A New Model for Neurodegenerative Disease
Acessos: 124
pig model
Pesquisar
Início
O que é A-T?
Notícias
admin@ataxiatelangiectasia.es